Have a feature idea you'd love to see implemented?
Let us know!
JANX Janux Therapeutics Inc
Price (delayed)
$46.5
Market cap
$2.44B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$2.44B
Highlights
JANX's equity has surged by 88% year-on-year
Janux Therapeutics's debt has decreased by 6% YoY
The quick ratio has soared by 58% year-on-year but it is down by 32% since the previous quarter
The revenue has soared by 54% YoY but it has contracted by 14% from the previous quarter
Key stats
What are the main financial stats of JANX
Market
Valuations
Earnings
Shares outstanding
52.48M
Market cap
$2.44B
Enterprise value
$2.44B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.7
Price to sales (P/S)
194.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
186.7
Revenue
$13.05M
EBIT
-$60.54M
EBITDA
-$58.46M
Free cash flow
-$37.82M
Per share
Balance sheet
Liquidity
EPS
-$1.16
Free cash flow per share
-$0.69
Book value per share
$12.58
Revenue per share
$0.24
TBVPS
$12.72
Total assets
$695.02M
Total liabilities
$38.92M
Debt
$23.43M
Equity
$656.1M
Working capital
$649.15M
Debt to equity
0.04
Current ratio
38.8
Quick ratio
38.37
Net debt/EBITDA
0.07
Margins
Efficiency
Dividend
EBITDA margin
-448%
Gross margin
100%
Net margin
-463.9%
Operating margin
-658.8%
Return on assets
-9.9%
Return on equity
-10.5%
Return on invested capital
-10.9%
Return on capital employed
-8.9%
Return on sales
-463.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JANX stock price
How has the Janux Therapeutics stock price performed over time
Intraday
-5.02%
1 week
-9%
1 month
-7.9%
1 year
434.48%
YTD
333.36%
QTD
2.36%
Financial performance
How have Janux Therapeutics's revenue and profit performed over time
Revenue
$13.05M
Gross profit
$13.05M
Operating income
-$85.96M
Net income
-$60.54M
Gross margin
100%
Net margin
-463.9%
Janux Therapeutics's net margin has shrunk by 59% QoQ but it has increased by 37% YoY
The revenue has soared by 54% YoY but it has contracted by 14% from the previous quarter
JANX's gross profit has soared by 54% YoY but it is down by 14% QoQ
The operating margin has plunged by 51% from the previous quarter but it has grown by 26% YoY
Growth
What is Janux Therapeutics's growth rate over time
Valuation
What is Janux Therapeutics stock price valuation
P/E
N/A
P/B
3.7
P/S
194.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
186.7
The EPS has contracted by 29% from the previous quarter but it has grown by 22% YoY
JANX's equity has surged by 88% year-on-year
JANX's P/B is 32% above its last 4 quarters average of 2.8
The revenue has soared by 54% YoY but it has contracted by 14% from the previous quarter
The P/S is 19% more than the last 4 quarters average of 163.2
Efficiency
How efficient is Janux Therapeutics business performance
The ROS has plunged by 59% from the previous quarter but it has grown by 37% YoY
JANX's return on equity is up by 46% year-on-year but it is down by 19% since the previous quarter
The ROA has grown by 43% YoY but it has contracted by 21% from the previous quarter
The return on invested capital is up by 41% year-on-year but it has declined by 20% since the previous quarter
Dividends
What is JANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JANX.
Financial health
How did Janux Therapeutics financials performed over time
Janux Therapeutics's total assets has surged by 80% YoY
The quick ratio has soared by 58% year-on-year but it is down by 32% since the previous quarter
Janux Therapeutics's debt is 96% lower than its equity
JANX's equity has surged by 88% year-on-year
Janux Therapeutics's debt to equity has decreased by 43% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.